As researchers learn more about tumor heterogeneity, imaging and biopsies are becoming increasingly important.

Whenever we establish a diagnosis, it's based on one biopsy sample.

We believe that this is representative of the entire tumor burden.

The other met at other site in the bone or another site in the liver or the primary tumor.

would be mostly similar.

However, that's not entirely true.

Now, it's not fair for us to poke needles because these are invasive procedures.

As patients, clinicians, and researchers continue learning more about neuroendocrine cancer, NETRF remains focused on connecting those pieces, advancing research, supporting education, and helping patients and families better understand the road ahead.